Hematological Cancers to See Incidence Growth, Says GBI Research in Its Report Available at MarketPublishers.com

27 Jul 2016 • by Natalie Aster

LONDON – Belonging to a class of cancer affecting blood as well as bone marrow and lymph nodes, hematological malignancies comprise different forms of leukemia, myeloma and lymphoma. As of 2011, these malignancies formed 9% of all malignancies being newly diagnosed in the USA. Lymphomas prevail over other malignancies. Prevalence of these types of malignancies is on the rise and this growth is mainly associated with the population ageing. 

The hematological cancer pipeline forms one of the most innovative pipeline in this industry, and there are more than 460 first-in-class products in it.

There are approximately 130 cancer immunotherapies at different stages of development, and this makes them the most common ones. The signal transduction group of targets follows them.

Topical research report “Frontier Pharma: Hematological Cancers - Highly Innovative Pipeline Continues Trend towards Targeted, Patient-Specific Therapies” drawn up by GBI Research offers a comprehensive analysis of the world’s market for hematological cancers. The study covers unmet needs this industry has. It delves deep the case of innovation existing in the hematological cancers’ domain.

The report provides an up-close look at the clinical and commercial landscape, thus shedding light on each disease. The research study assesses innovations in the product pipeline. It evaluates first-in-class targets and contains strategic consolidations.

Key Questions Answered in the Research Report Comprise:

  • Which classes of drugs lead the race?
  • What are extra benefits can boast newly approved therapies being introduced to the marketplace?
  • Which molecular targets are the most frequent ones in the pipeline?
  • To which target families do first-in-class products belong?
  • And more

More in-demand studies by our partner can be found at GBI Research page.


The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970